| Factor |
Patients no
|
P Value |
| CR |
PR |
Sex
Male
Female |
45 (64.2%)
15 (21.4%) |
7 (10.2%)
3 (4.2%) |
0.889 |
| Pathological subtype |
|
|
0.133 |
| Non keratinizing |
9 (12.9%) |
4 (5.7%) |
| Undifferentiated |
45 (64.3%) |
5 (7.1%) |
| Basaloid |
5 (7.1%) |
2 (2.9 %) |
| Baseline T stage |
|
|
|
| T1 |
7 (10.1%) |
|
|
| T2 |
26 (37.1%) |
|
<0 .001 |
| T3 |
25 (35.7%) |
4 (5.7%) |
|
| T4 |
3 (4.3%) |
5 (7.1%) |
|
| Baseline N stage |
|
|
|
| N0 |
18 (25.7%) |
|
0.002 |
| N1 |
34 (48.6%) |
5 (7.1%) |
|
| N2
N3 |
9 (12.9%)
3 (4.3%) |
1 (1.4%) |
|
| Radiation Technique |
|
|
|
| 3DCRT |
48 (68.6%) |
3 (4.2%) |
0.412 |
| IMRT |
15 (21.4%) |
4 (5.8%) |
|
| Concurrent Chemo-radiation Break |
|
|
|
| < 7 Days |
56 (80%) |
4 (5.7%) |
<0 .001 |
| >7 Days |
3 (4.3%) |
7 (10 %) |
|
Pretreatment Pet- CTSUVmax primary
<8
≥ 8 |
32 (45.7%)
28 (40%) |
6 (8.6%)
4 (5.7%) |
041 |
|
